Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $ARDX
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/11/2024 | $11.00 → $5.50 | Buy → Neutral | H.C. Wainwright |
7/2/2024 | $15.00 → $7.00 | Overweight → Neutral | Piper Sandler |
4/5/2024 | $14.00 | Outperform | Leerink Partners |
12/18/2023 | $12.00 | Strong Buy | Raymond James |
9/7/2023 | $9.00 | Buy | H.C. Wainwright |
8/25/2023 | $5.00 → $10.00 | Neutral → Overweight | Cantor Fitzgerald |
3/3/2023 | $3.00 → $6.00 | Neutral → Outperform | Wedbush |
11/17/2022 | $3.00 → $8.00 | Neutral → Overweight | Piper Sandler |
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales Company reaffirms combined peak sales of IBSRELA and XPHOZAH of $1.75 Billion Company ended FY 2024 with $250.1 million in cash, cash equivalents and investments Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen's 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event. About Ardelyx, I
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be avail
Ardelyx downgraded by H.C. Wainwright with a new price target
H.C. Wainwright downgraded Ardelyx from Buy to Neutral and set a new price target of $5.50 from $11.00 previously
Ardelyx downgraded by Piper Sandler with a new price target
Piper Sandler downgraded Ardelyx from Overweight to Neutral and set a new price target of $7.00 from $15.00 previously
Leerink Partners initiated coverage on Ardelyx with a new price target
Leerink Partners initiated coverage of Ardelyx with a rating of Outperform and set a new price target of $14.00
Director Mott David M bought $992,672 worth of shares (199,000 units at $4.99), increasing direct ownership by 11% to 1,937,765 units (SEC Form 4)
4 - ARDELYX, INC. (0001437402) (Issuer)
Director Mott David M bought $996,580 worth of shares (213,300 units at $4.67), increasing direct ownership by 15% to 1,638,765 units (SEC Form 4)
4 - ARDELYX, INC. (0001437402) (Issuer)
Director Mott David M bought $996,598 worth of shares (215,868 units at $4.62), increasing direct ownership by 18% to 1,425,465 units (SEC Form 4)
4 - ARDELYX, INC. (0001437402) (Issuer)
Chief Medical Officer Williams Laura A sold $27,783 worth of shares (4,941 units at $5.62), decreasing direct ownership by 2% to 303,804 units (SEC Form 4)
4 - ARDELYX, INC. (0001437402) (Issuer)
Chief Financial Officer Renz Justin A sold $29,077 worth of shares (5,171 units at $5.62), decreasing direct ownership by 2% to 285,968 units (SEC Form 4)
4 - ARDELYX, INC. (0001437402) (Issuer)
President & CEO Raab Michael sold $129,124 worth of shares (22,964 units at $5.62), decreasing direct ownership by 2% to 1,085,755 units (SEC Form 4)
4 - ARDELYX, INC. (0001437402) (Issuer)
SEC Form 10-K filed by Ardelyx Inc.
10-K - ARDELYX, INC. (0001437402) (Filer)
Ardelyx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - ARDELYX, INC. (0001437402) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Ardelyx Inc.
SCHEDULE 13G/A - ARDELYX, INC. (0001437402) (Subject)
FDA Approval for XPHOZAH issued to ARDELYX INC
Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
FDA Approval for XPHOZAH issued to ARDELYX INC
Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling
FDA Approval for XPHOZA™ issued to ARDELYX INC
Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Eric Foster as the company's Chief Commercial Officer. Mr. Foster is an experienced leader with more than 23 years of commercial experience for significant global biotech and pharmaceutical companies across numerous complex rare disease and specialty markets. Mr. Foster will be responsible for leading all commercial strategies for the company's two first-in-class medicines, IBSRELA® (tenapanor) and XPHOZAH® (te
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy. Mr. Kelliher, an accomplished leader with more than 20 years of experience in the biopharmaceutical industry, brings to Ardelyx an extensive array of mergers and acquisitions, business development, strategy, finance and operational leadership expertise from leading biotechnology and global pharmaceutical companies.
Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. "We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer to commercializing potentially curative treatments for people with life-threatening diseases," said Intellia President and Chief Executive Officer John Leonard, M.D. "We are very fortunate to benef
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales Company reaffirms combined peak sales of IBSRELA and XPHOZAH of $1.75 Billion Company ended FY 2024 with $250.1 million in cash, cash equivalents and investments Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be avail
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million XPHOZAH generates $51.5 million in net product sales revenue Company ends Q3 with approximately $190 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2024 and prov
Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)